

### AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows:

At page 1, please delete the following:

This application is a Continuation Application under 37 CFR 1.53(b) and claims priority under Title 35, United States Code 119(e) from Provisional Application Serial No. 60/126,673, filed March 29, 1999 and to Application Serial No. 09/537,789, filed March 29, 2000.

And insert therefor:


This application is a Continuation Application under 37 CFR 1.53(b) and claims priority under Title 35, United States Code 119(e) from Provisional Application Serial No. 60/126,673, filed March 29, 1999 and to Application Serial No. 09/537,789, filed March 29, 2000, now US 6,613,874 issued September 2, 2003.

At page 1, after the section titled "Cross Reference To Related Applications" please insert therefor:


### REFERENCE TO A SEQUENCE LISTING

This Application incorporates by reference in accordance with 37 CFR 1.82(e) a Sequence Listing appendix from Application Serial No. 09/537,789 filed March 29, 2000, now US 6,613,874 issued September 2, 2003.


At page 32 please delete the figure:




At page 32 please delete the figure:




At page 32 please delete the figure:




At page 33 please delete the figure:




At page 33 please delete the figure:




At page 33 please delete the figure:




At page 33 please delete the figure:




At page 34 please delete the figure:




At page 34 please delete the figure:




At page 34 please delete the figure:



At page 35 please delete the figure:



At page 35 please delete the figure:



At the bottom of page 5, please insert the following:

### DESCRIPTION OF THE FIGURES

Figures 1-12 describe the relative selectivity of 10 analogs of the present invention (Figures 1-10) and two known non-selective agonists (Figures 11 and 12). The relative affinities of the 10 analogs and 2 standards for each melanocortin receptor, are expressed as a per cent of c-AMP production relative to a standard c-AMP producing non-selective agonist, norleucine-4-D-phenylalanine-7-melanocyte stimulating hormone (NDP-MSH). The NDP-MSH standard was evaluated for the level of c-AMP release at each receptor and the values for the test samples were expressed as a % of the maximal amount produced by NDP-MSH. 1R, 3R, and 4R correspond respectively to the MC-1, MC-3, and MC-4 receptors. The % c-AMP produced by each compound was measured at concentrations from  $1 \times 10^{-8}$  to  $1 \times 10^{-4}$  molar.

Figure 1 shows the % cAMP activity at various concentrations for Ac-a[**DYfRWGK**]-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over the MC-3R and MC-1R.

Figure 2 shows the % cAMP activity at various concentrations for Ac-a[**EYfRWG(Orn)**]-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over the MC-3R and MC-1R.

Figure 3 shows the % cAMP activity at various concentrations for Ac-a[**DyfRWGK**]-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over the MC-3R and MC-1R.

Figure 4 shows the % cAMP activity at various concentrations for Ac-a[**EYfRWGK**]-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over the MC-3R and MC-1R.

Figure 5 shows the % cAMP activity at various concentrations for Ac-a**DYfRWGK**-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over the MC-3R and MC-1R.

Figure 6 shows the % cAMP activity at various concentrations for Ac-a[**DYfRWG(Orn)**]-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over MC-1R.

Figure 7 shows the % cAMP activity at various concentrations for Ac-a**DYfRWG(Orn)**-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over MC-1R.

Figure 8 shows the % cAMP activity at various concentrations for Ac-aEYfRWG(Orn)-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over MC-1R.

Figure 9 shows the % cAMP activity at various concentrations for Ac-aDYfRWK-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over MC-1R.

Figure 10 shows the % cAMP activity at various concentrations for Ac-[DYfRWGK]-NH<sub>2</sub> thereby demonstrating the selectivity of this analog for MC-4R over the MC-3R and MC-1R.

Figure 11 shows the % cAMP activity at various concentrations for Ac-SYSNIeEHfRWGKPV-NH<sub>2</sub>, a non-selective agonist, thereby demonstrating how the compounds of Figures 1-10 demonstrate selectivity for MC-4R over the MC-3R and MC-1R.

Figure 12 shows the % cAMP activity at various concentrations for Ac-NIeDHfRWGK-NH<sub>2</sub>, a non-selective agonist, thereby demonstrating how the compounds of Figures 1-10 demonstrate selectivity for MC-4R, over the MC-3R and MC-1R.